Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Astellas Pharma Inc., National Heart, Lung, and Blood Institute (NHLBI)
Scientific Title
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/ITD AML